GlaxoSmithKline drops anti-obesity drug as profits fall
Friday 11 February 2005
Jean Pierre Garnier, the chief executive, said 2004 was "always going to be a tough year" for the company as many of its patents ran out, opening the door for rival generic versions of its drugs to go on sale. It also announced it had dropped the development of an anti-obesity drug, after clinical trials proved disappointing.
Sales across the group fell 5 per cent to pounds 20.3bn in 2004, hit by generic rivals to its antidepressants Wellbutrin and Paxil. Pre-tax profits for the year declined 9 per cent to pounds 6.1bn. Mr Garnier said the group had taken the worst hit from generic drugs for some years, and it now had 15 key new drugs that are due to produce crucial testing results in 2005. "We are going to find out if all our efforts to develop our pipeline will pay off," he said.
One of this year's most eagerly awaited findings will be test results of its latest HIV treatment. Dr Tachi Yamada, the head of research and development, said: "Many people think HIV is purely a problem in the developing world, but it is still an issue across the globe."
Most HIV treatments attempt to kill the virus, but GSK's treatment targets the cells the HIV virus infects, preventing it from spreading.
Mr Garnier said investors had underestimated the potential for its cervical cancer treatment, which it hopes will vaccinate millions of women against the disease. It is due to enter its final testing phase, and GSK claims it could eradicate 70 per cent of cervical cancer cases. "Most analyst consensus on the Cervarix vaccine is too low. Demand is going to expand dramatically," he said. Analysts are forecasting sales of $1bn.
Another vaccine GSK is pinning its hopes on this year works against the most common cause of diarrhoea, which infects 125 million children and kills 440,000 people a year.
The company released the findings of a study into its asthma treatment yesterday, which compared its success with a similar drug from its rival AstraZeneca. GSK claims research into the effectiveness of Seretide showed its patients had about an extra 24 days free from symptoms than patients taking AstraZeneca's Symbicort.
David Cameron stung by jellyfish: PM hurt after ignoring advice of locals while on holiday
South Korea ferry: Vice principal rescued from sinking ship found hanged
Oscar Pistorius trial: The case against Oscar Pistorius – and why the prosecution claims his story doesn't add up
Peaches Geldof funeral: Private ceremony to be held at same place as her mother Paula Yates on Easter Monday
Shropshire criminals ‘using unmanned drones and infrared cameras to find illegal cannabis farms’ – and then steal from the growers
The food poverty scandal that shames Britain: Nearly 1m people rely on handouts to eat – and benefit reforms may be to blame
US Navy christens huge $3 billion destroyer ship USS Zumwalt that appears as a fishing boat on enemy radar
Scottish independence: It is the English who should be on their knees, begging the Scots to vote ‘No’
Nigel Farage fatigue? Half of voters ‘immune’ to Ukip’s appeal
Nigel Farage on Have I Got News For You: Ukip leader ridiculed over expenses and party 'fruitcakes'
Nigel Farage: I’m taking on the status quo, and the Establishment’s fighting back
- 1 Are you turning into your dad? The top ten signs you've embraced dad-ism revealed as survey says 38 is age men turn into their father
- 2 Overheard in Waitrose: documenting the chatter in 'Britain's poshest supermarket'
- 3 Video of British Muslims dancing to Pharrell Williams's hit Happy attacked as 'sinful'
- 4 24 people applied for the 'world's toughest job', here are their interviews
- 5 Grace Dent on TV: Game of Thrones has jumped the shark
iJobs Money & Business
£150.00 per week: QA Apprenticeships: This company has been providing on site ...
£221.25 per week: QA Apprenticeships: This company is a well established Inter...
£40000 - £50000 per annum: Harrington Starr: Client Relationship Manager - SQL...
£35000 - £50000 per annum: Pro-Recruitment Group: Take your chance to join the...